Life Sciences Greenhouse of Pennsylvania

What Life Sciences Greenhouse of Pennsylvania does

Life Sciences Greenhouse Investments (LSGI) is an evergreen venture fund established in 2002 through Pennsylvania state legislation funded by the Master Tobacco Settlement Act. Originally incorporated as Life Sciences Greenhouse of Central Pennsylvania and rebranded to its current name in January 2023, LSGI operates from a single headquarters in Harrisburg, PA, with a small investment team (1–10 employees) led by President & CEO Michele Washko and Executive Vice President Greg Jackson, Ph.D. The fund's stated mission is to strengthen Pennsylvania's life sciences ecosystem by providing early-stage capital and operational expertise to startups developing drug discovery, diagnostics, medical device, and healthcare technology innovations.

LSGI's core offering is structured equity capital deployed in milestone-driven tranches, typically beginning at $250,000–$500,000 and scaling to up to $5 million per company across seed and Series A rounds. The fund complements its equity investments with non-dilutive Business Opportunity Grants of up to $100,000 (by invitation only) to fund market studies, technical consulting, and legal diligence. Portfolio companies also gain access to a curated network of scientific and business advisors, board participation by LSGI investment professionals, and introductions to co-investors such as Ben Franklin Technology Partners, the Pennsylvania Angel Network, and Mid Atlantic Bio Angels. Investments are geographically restricted to companies with a documented Pennsylvania tie — headquarters, facility, founders, or spin-out from a Pennsylvania institution. Notable portfolio companies include Avisi Technologies (nanotechnology ocular implant), Ilico Genetics (AI-enabled cancer diagnostics), Saladax Biomedical (therapeutic drug monitoring immunoassays), Indigo Biosciences (cell-based reporter assays), SIRPant Immunotherapeutics (macrophage-based immunotherapy), and Forma Medical (FDA-approved foot surgery device).

LSGI's revenue mechanics differ fundamentally from a commercial enterprise: as an evergreen fund, it is capitalized by a foundational $37 million allocation from the Master Tobacco Settlement Act, supplemented by $14.76 million in 2022 SSBCI venture capital from the Pennsylvania Department of Community and Economic Development, and reinvests returns generated from portfolio exits back into new investments rather than distributing them to LPs. Since inception, LSGI reports $44 million of direct investment into 86 companies and projects, catalyzing $773 million in follow-on capital from other investors and supporting 205 products in development or on the market. The entity operates as a quasi-governmental economic development vehicle under the oversight of the Pennsylvania DCED, with no private equity or VC firm ownership.

Name

Life Sciences Greenhouse of Pennsylvania

Legal name

Life Sciences Greenhouse Investments

Website

https://lsgpa.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

1–10 employees

Short description

Life Sciences Greenhouse Investments (LSGI) is an evergreen venture fund established by Pennsylvania state legislation in 2002, providing early-stage equity capital ($250K–$5M) and operational expertise to life sciences startups headquartered in or tied to Pennsylvania.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Venture capital funding
• Life sciences investment
• Early-stage equity financing
• Medical device funding
• Biotechnology venture capital

Headquarters

HQ city

Harrisburg

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Equity Investment Returns: LSGI generates returns by taking equity stakes in early-stage life science companies. As an evergreen venture fund founded in 2002, it provides capital in exchange for ownership and seeks exit events (M&A, IPO) to realize returns. The fund is evergreen, meaning it reinvests capital rather than returning it to traditional LP investors, and is financed by a grant from the Commonwealth of Pennsylvania's Department of Community and Economic Development plus returns from its portfolio.
2. Business Opportunity Grants: LSGI offers non-dilutive Business Opportunity Grants of up to $100,000 to early-stage companies to fund market studies, technical consulting, and legal consulting. These grants help fill due diligence gaps and are by invitation only, potentially leading to equity investment relationships.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Life Sciences Greenhouse Investments (LSGI) is an evergreen venture fund that provides early-stage equity capital and operational expertise to Pennsylvania-based life sciences companies. Typical initial investments range from $250,000 to $500,000 in milestone-driven tranches, with total commitments up to $5 million per company across seed and Series A rounds. The fund also offers invitation-only Business Opportunity Grants of up to $100,000 for market studies, technical consulting, and legal consulting to support due diligence.

Product overview

Life Sciences Greenhouse Investments (LSGI) is an evergreen venture fund, not a product company. It provides early-stage capital investment (typically $250,000-$500,000 initial investments, up to $5 million per company) and operational expertise to life science startups. LSGI does not develop or sell its own products or services. Instead, it funds and supports portfolio companies working on drug discovery, diagnostics, medical devices, and healthcare technology solutions. The organization offers business advice, connects companies to industry networks, and helps with management talent acquisition and facility location.

Differentiator

Problem solved

Functional benefit

Products and services

• Seed and Series A Equity Investments Equity investments of $250,000–$500,000 initial (up to $5 million total per company) in Pennsylvania-based early-stage life sciences companies developing drug discovery, diagnostics, medical devices, and life sciences tools. Funds released in milestone-driven tranches with operational support and access to scientific and business advisor networks.
• Business Opportunity Grants
• Applied Expertise and Operational Support Operational and advisory support provided alongside equity investments, including connections to a curated network of business and scientific advisors, board participation by LSGI investment professionals, support in identifying management talent, facilities, and follow-on funding sources.

Quantifiable outcome

• $44 million invested into 86 companies, catalyzing $773 million in follow-on funding from other investors
• +3 more outcomes

Named customers15 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• ArgoPondcoreStrategic or Co-development Partner · 24 January 2023LSGI announced a new partnership with ArgoPond, a Philadelphia-based (Bala Cynwyd, PA) investment diligence firm with expertise in medical devices and diagnostics. ArgoPond provides technical and business advice on both sides of early life science investment deals—serving venture capital, private equity, and private-public partnerships, as well as early-stage companies seeking to position themselves for investment. The partnership was designed to accelerate the pace of life science investments in Pennsylvania by bringing ArgoPond's global perspective, professional network, fresh evaluation methodologies, and specialized expertise in emerging healthcare trends to LSGI's investment decisions. ArgoPond was founded in 2016 by Dr. John Younger, a former physician-scientist and investor.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Ben Franklin Technology Partners: Pennsylvania state-funded technology investment organization that co-invests with LSGI and provides seed/early-stage capital to PA-based startups across technology and life sciences. Most direct comparable given shared geography, state funding lineage, and overlapping portfolio.
• BioAdvance: New Jersey-based evergreen venture fund investing in early-stage life sciences companies, established with state-backed funding. Closest analogue in mission and structure (state-backed evergreen life sciences VC) though operating in NJ.

Regional players

• Massachusetts Life Sciences Center: Massachusetts quasi-governmental agency funding early-stage life sciences companies through grants and investments. Comparable in state-backed life sciences funding mission, but serves the Massachusetts ecosystem rather than Pennsylvania.
• Connecticut Innovations: Connecticut's state-backed venture capital and investment arm that funds early-stage technology and life sciences companies. Similar state-funded evergreen venture model but operating in a different geography.
• Maryland Technology Development Corporation (TEDCO): Maryland's state-chartered technology economic development corporation that invests in early-stage technology and life sciences companies. Comparable state-backed early-stage investment model serving a different regional ecosystem.
• BioGenerator: St. Louis-based life sciences startup creation and investment organization supporting early-stage biotech companies. Comparable focus on life sciences seed-stage investing, though privately funded rather than state-appropriated.
• Empire State Development's New York Ventures: New York State's venture capital arm providing early- and growth-stage capital to companies in New York. Comparable in state-government-backed early-stage investment model.

Broad incumbents

• ARCH Venture Partners: Large U.S. venture firm specializing in early-stage life sciences and physical sciences companies spun out of universities and research institutions. Comparable in life sciences early-stage focus, but operates nationally with private LP capital at much larger fund sizes.
• SR One (GlaxoSmithKline): Translational and early-stage life sciences venture investor that funds biotech companies across geographies and therapeutic areas. Comparable life sciences early-stage mandate, with private LP-backed fund model versus LSGI's evergreen state-funded structure.

Others

• Johnson & Johnson Innovation – JLABS: Global network of life sciences incubators supporting early-stage companies with lab space, mentorship, and connections. Comparable ecosystem-enabling role for early-stage life sciences companies (and incubator for LSGI portfolio company Avisi), though operates as a corporate incubator rather than a venture fund.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/lsgpa
• Xx.com/LSGPA
• Facebookfacebook.com/LSGPA

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments21 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Life Sciences Greenhouse of Pennsylvania